Incorporating genetic testing and counseling for prostate cancer into clinical practice
“I think this is an area that needs to be really personalized to each clinical practice,” says Alicia K. Morgans, MD, MPH.
In this video, Alicia K. Morgans, MD, MPH, discusses the practices she implements regarding germline and somatic testing in patients with advanced prostate cancer. These ideas were focused on in her presentation, “Advanced disease: incorporating molecular markers and genomic studies into therapy,” presented recently at the 2021 Society of Urologic Oncology Annual Meeting. Morgans is a genitourinary medical oncologist and medical director of the Survivorship Program at the Dana-Farber Cancer Institute in Boston, Massachusetts.
Grant to fund research on biomarkers for toxicity from prostate cancer radiation
July 11th 2024“By understanding the mirSNP genetic markers that predispose patients to adverse side effects from cancer therapy we can tailor these therapies to minimize harm and maximize efficacy," says Joanne B. Weidhaas, MD, PhD, MS.
Gene-expression signature could serve as biomarker for recurrence in ccRCC
June 26th 2024“Even when we adjusted for other clinical variables, like age or grade of tumor, this signature was still independently associated with recurrence after treatment for this form of kidney cancer," says Simpa S. Salami, MD, MPH.
